Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

1.940 -0.140 (-6.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,145,392
Open 2.040
Bid (Size) 1.940 (44)
Ask (Size) 1.950 (47)
Prev. Close 2.080
Today's Range 1.920 - 2.069
52wk Range 1.740 - 6.310
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
23andMe Holding's Return On Capital Employed Overview
 
Via Benzinga
Recap: 23andMe Holding Q4 Earnings
 
Via Benzinga

Performance

YTD
-7.62%
-7.62%
1 Month
-3.96%
-3.96%
3 Month
-22.71%
-22.71%
6 Month
-30.96%
-30.96%
1 Year
-35.33%
-35.33%

More News

Read More
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe Holding's Earnings Outlook
Via Benzinga
Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
Via The Motley Fool
3 Key Biotech Trends for 2023 And Beyond
Via The Motley Fool
Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich … or Broke.
Via InvestorPlace
This Genetics Stock Could Have Massive Long-Term Potential
Via The Motley Fool
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
From 23andMe, Inc.
Via GlobeNewswire
3 Personalized Medicine Stocks to Buy for Long-Time Returns
Via InvestorPlace
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
23andMe Releases New Report Revealing Likelihood of Developing Lupus
From 23andMe Holding Co.
Via GlobeNewswire
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
From 23andMe Holding Co.
Via GlobeNewswire
BELLUS Health, Sunrun And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
Via Benzinga
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
From 23andMe Holding Co.
Via GlobeNewswire
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
From 23andMe Holding Co.
Via GlobeNewswire
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
From 23andMe Holding Co.
Via GlobeNewswire
3 Key Ways That Artificial Intelligence Will Disrupt Biotech Stocks
Via The Motley Fool
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
From 23andMe Holding Co.
Via GlobeNewswire
AI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023
Via The Motley Fool
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
From 23andMe Holding Co.
Via GlobeNewswire
2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise
Via The Motley Fool
2 High-Growth Stocks That Could Double Your Money in 5 Years or Less
Via The Motley Fool
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
From 23andMe Holding Co.
Via GlobeNewswire
23andMe to Present at Upcoming Investor Conferences
From 23andMe Holding Co.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.